View More Recent Stories
-
Truist Reiterates Buy Rating on Protagonist Therapeutics (PTGX) Following KOL Feedback
-
JMP Securities Reiterates Market Outperform Rating on Protagonist Therapeutics (PTGX)
-
Jefferies Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
Protagonist Therapeutics Reports Granting of Inducement Awards
-
Clear Street Starts Protagonist Therapeutics (PTGX) at Buy, Top Pick
-
BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
BMO Capital Starts Protagonist Therapeutics (PTGX) at Outperform
-
Truist Securities Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
Protagonist Therapeutics (PTGX) PT Raised to $67 at BTIG
-
H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
Protagonist Therapeutics (PTGX) Tops Q3 EPS by 4c
-
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
TD Cowen Starts Protagonist Therapeutics (PTGX) at Buy
-
Protagonist Therapeutics (PTGX) PT Raised to $50 at H.C. Wainwright
-
Truist Securities Starts Protagonist Therapeutics (PTGX) at Buy
-
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
-
Protagonist Therapeutics (PTGX) PT Raised to $40 at H.C. Wainwright
-
Protagonist Therapeutics (PTGX) Tops Q2 EPS by 10c
-
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics (PTGX) Appoints Newman Yeilding as Chief Scientific Advisor
-
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
-
Protagonist Therapeutics (PTGX) PT Raised to $51 at BTIG
-
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
-
These are BTIG's top pick stocks for H2 2024
-
Protagonist Therapeutics (PTGX) to Join S&P SmallCap 600
-
H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
Protagonist Therapeutics (PTGX) PT Raised to $39 at JPMorgan

